Product Code: RP-ID-10070640 |
Published Date: 21 Mar 2025 |
Region: Global |
Category: Healthcare & Pharmaceuticals |
Report ID: 10070640
Market Overview:
Chimeric Antigen Receptor (CAR-T) Cell Therapy Market Segmentation by Type (ABECMA, YESCARTA, BREYANZI, KYMRIAH, TECARTUS, and Others); by Application (Cancer, Diffuse Large B-Cell Lymphoma, Acute Lymphoblastic Leukemia and Others); and by End User (Hospitals, Specialty Clinics, and Others)-Global Demand Analysis & Opportunity Outlook 2031
Global Chimeric Antigen Receptor (CAR-T) Cell Therapy Market Highlights Over 2022 - 2031
The global chimeric antigen receptor (CAR-T) cell therapy market garnered revenue of approximately USD 1,000 million by the end of 2021. The market is expected to grow at a CAGR of ~30% over the forecast period, i.e., 2022 – 2031. The growth of the market can majorly be attributed to the rise in cancer cases worldwide. According to International Agency for Research on Cancer (IARC), the global burden of cancer cases is expected to rise by 27.5 million and death rates are estimated to reach up to 16.3 million by the year 2040. Additionally, an increase in product approvals by The U.S. Food and Drug Administration makes the global chimeric antigen receptor (CAR-T) cell therapy market lucrative for investments by the key players.
CLICK TO DOWNLOAD A SAMPLE REPORT
Moreover, increasing preference for CAR-T cell therapy amongst oncologists for individuals who are suffering from cancer is anticipated to bolster market growth. The preference for this therapy can be attributed to the fact that this therapy shows prolonged durability against the cancer-causing cells and has fewer side effects. Furthermore, there is an increase in continuous research & development in the field of CAR-T cell therapy products which is expected to drive the market growth. However, risks associated with the therapy and the huge cost of cancer treatment are expected to hinder the growth of the market.
On the basis of type, the market is segmented into ABECMA, YESCARTA, BREYANZI, KYMRIAH, TECARTUS, and others, out of which, the YESCARTA segment is anticipated to hold the largest share of the market over the forecast period, owing to its efficient results in treating relapsed or refractory large B-cell lymphoma in adult patients. This type has a greater success rate and fewer side effects.
The market is further segmented on the basis of application into cancer, diffuse large-B cell lymphoma, acute lymphoblastic leukemia, and others, under which the cancer segment is estimated to have the largest share in the market during the forecast period. The growing prevalence of cancer cases worldwide, technological advancements in cancer therapy, and the rise in the number of cell therapy are anticipated to drive the growth of the cancer segment in the coming years.
Global Chimeric Antigen Receptor (CAR-T) Cell Therapy Market Regional Synopsis
Regionally, the global chimeric antigen receptor (CAR-T) cell therapy market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. The market in North America region is estimated to witness noteworthy growth over the forecast period on the back of rising cancer cases in the region. The aged population is highly prone to cancer and countries in the region, such as the United States, poses high number of geriatric people who are vulnerable towards cancer disease. According to the National Cancer Institute during the year 2020, it was estimated that the newly diagnosed cases of cancer recorded close to 1806590 cases in the United States.
Market Segmentation
Our in-depth analysis of the global chimeric antigen receptor (CAR-T) cell therapy market includes the following segments:
By Type
-
ABECMA
-
YESCARTA
-
BREYANZI
-
KYMRIAH
-
TECARTUS
-
Others
By Application
-
Cancer
-
Diffuse Large-B Cell Lymphoma
-
Acute Lymphoblastic Leukemia
-
Others
By End-User
-
Hospitals
-
Specialty Clinics
-
Others
Growth Drivers and Challenges Impacting the Growth of the Global Chimeric Antigen Receptor (CAR-T) Cell Therapy Market
Growth Drivers
-
Rising burden of cancer cases worldwide
-
Growing research & development in the field of CAR-T cell therapy products
Challenges
-
Risk factors included during the conduct of CAR-T cell therapy
-
Difficulties in developing CAR-T cell therapy products
Key Companies Dominating the Global Chimeric Antigen Receptor (CAR-T) Cell Therapy Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global chimeric antigen receptor (CAR-T) cell therapy market that are included in our report are Fate Therapeutics, Novartis AG, Amgen Inc., Bristol-Myers Squibb Company, Sorrento Therapeutics, Inc., Gilead Sciences, Inc., bluebird bio, Inc., Immune Therapeutics, INC., Bellicum Pharmaceuticals, Inc., Pfizer Inc., and others.
Latest Developments in the Global Chimeric Antigen Receptor (CAR-T) Cell Therapy Market:
-
December 2021: T-Charge, which is Novartis' next-generation CAR-T platform, was launched at the 63rd American Society of Hematology Annual Meeting & Exposition (ASH) 2021. T-Charge is designed to serve as a cornerstone for a number of novel experimental CAR-T cell treatments. Furthermore, Novartis is expected to release clinical results from Phase I clinical studies with YTB323 (anti-CD19) and PHE885 (anti-BCMA), CAR-T cell therapies. These CAR-T-charged therapies have the ability to yield better and more effective results.
-
January 2020:One of the subsidiaries of Gilead Sciences, Inc., which is also engaged in the development of innovative cancer immunotherapies, Kite, announced that one of its products KTE-X19 is now under evaluation by the European Medicines Agency (EMA) against the Marketing Authorization Application (MAA) raised by the company. KTE-X19 is the investigational chimeric antigen receptor (CAR-T) cell therapy, which is used for the treatment of relapsed or refractory mantle cell lymphoma (MCL) amongst adult patients.
Key Reasons to Buy Our Report
-
The report covers detailed analysis comprising market share attained by each market segment and its sub-segments.
-
It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis and challenges that impact the market growth.
-
The report includes detailed company profiles of the major players dominating the market.
-
We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.
-
We provide customized reports as per the client's requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.
- Fate Therapeutics
- Novartis AG
- Amgen Inc.
- Bristol-Myers Squibb Company
- Sorrento Therapeutics Inc.
- Gilead Sciences, Inc.
- bluebird bio, Inc.
- Immune Therapeutics INC.
- Bellicum Pharmaceuticals Inc.
- Pfizer Inc
Related Reports
Proof of Quality & Reliability
